AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure

Data ReadoutnegativeWainuaNegative

AI Analysis

Summary

AstraZeneca's Wainua failed in late-stage development for ATTR-cardiomyopathy, but CEO Pascal Soriot stated the company remains on track to meet its 2030 revenue goal of $80 billion during Q2 earnings presentation.

Clinical Trial Data

Phase

late-stage

Primary Endpoint

Not Met

Financial Highlights

Revenue

$80 billion

Guidance

2030 revenue target of $80 billion

Outcome Details

Late-stage failure in ATTR-cardiomyopathy

Importance:5/10

Sentiment:

-0.30

late-stage failuredrug developmentearnings callrevenue guidanceATTR-cardiomyopathy

Related Companies

$AZN

Read the original article

Published by BioSpace on July 27, 2026 12:59 PM

Read Original